Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Biovica International

0.31 SEK+2.33 %2/10 17:29
Less than 1K followers

BIOVIC B

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor views
Compare
+2.33 %
-29.75 %
-13.76 %
-12.29 %
-17.03 %
-49.51 %
-95.04 %
-99.26 %
-97.01 %

Biovica International is a pharmaceutical company that focuses its research on cancer treatment. The company develops blood-based biomarker tests to monitor and evaluate cancer treatments. The tests analyze the risk of developing the enzyme thymidine kinase, an enzyme that is linked to tumor growth. The main focus is on the treatment of breast cancer. Biovica International was founded in 2008 and is headquartered in Uppsala.

Read more
Market cap
119.49M SEK
Turnover
90.91K SEK
Revenue
13.38M
EBIT %
-524.06 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Webcasts
Press releases
3rd party
ShowingAll content types

Forum discussions
Biovica is a Swedish biotechnology company founded in 2009. It was listed on the stock exchange in 2017. Its main product is the DiviTum TKa test: https://divitum.com/, which is a biomarker test that monitors and predicts treatment response in breast cancer. They received FDA approval...
8/31/2025, 1:45 PM
by OSAKEURPO
5
Biovica Q1 Interim report May 2025 – July 2025 - Biovica International AB 11.9 julkaistu osavuosi Tappio pieneni pikkaisen, mutta ei vielä merkittävää parannusta. Lisää myyntiä vaaditaan, että paastään luvattuun 2026 loppuvuoden voitolliseen tulokseen. Mielenkiinnolla seurailen mit...
9/18/2025, 12:09 PM
by Waldeboy
2
Read more on our forum
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
17/12
2026

Interim report Q2'27

11/3
2027

Interim report Q3'27

17/6
2027

Annual report '27

Regulatory press release2026-09-30 15:00

Kommuniké från extra bolagsstämma i Biovica International AB

Biovica International
Regulatory press release2026-09-30 15:00

Announcement from the extra general meeting in Biovica International AB

Biovica International
Regulatory press release2026-09-22 08:30

Biovica receives first work order under new Master Services Agreement for Phase 1 oncology study

Biovica International

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release2026-09-17 09:00

New meta-analysis strengthens clinical evidence for DiviTum TKa in metastatic breast cancer

Biovica International
Regulatory press release2026-09-16 18:05

Kommuniké från årsstämma i Biovica International AB

Biovica International
Regulatory press release2026-09-16 18:05

Announcement from the annual general meeting in Biovica International AB

Biovica International
Press release2026-09-14 14:54

Redeye: Biovica (Q1 review): Funded for strategy

Biovica International
Press release2026-09-10 09:00

BioStock: Biovica presenterar på Investing in Life Science 22 september

Biovica International
Press release2026-09-10 09:00

BioStock: Biovica to Present at Investing in Life Science on September 22

Biovica International
Regulatory press release2026-09-09 17:50

Biovica Q1 Rapport

Biovica International
Regulatory press release2026-09-09 17:50

Q1 Report - Focused Execution Driving Growth

Biovica International
Regulatory press release2026-09-09 17:46

KALLELSE TILL EXTRA BOLAGSSTÄMMA I BIOVICA INTERNATIONAL AB

Biovica International
Regulatory press release2026-09-09 17:46

NOTICE OF EXTRA GENERAL MEETING IN BIOVICA INTERNATIONAL AB

Biovica International
Regulatory press release2026-09-09 17:45

Biovica beslutar om en fullt garanterad företrädesemission om 29,2 MSEK

Biovica International
Regulatory press release2026-09-09 17:45

Biovica resolves on a fully guaranteed rights issue of SEK 29.2 million

Biovica International
Regulatory press release2026-08-27 12:00

Biovica expands Pharma Services business with new Master Services Agreement

Biovica International
Regulatory press release2026-08-25 09:00

New publication broadens the potential of DiviTum TKa in immuno-oncology

Biovica International
Press release2026-08-20 13:27

Redeye: Biovica: New Pharma Services work order and a new proposed board

Biovica International
Regulatory press release2026-08-19 09:00

Biovica receives new extensive Pharma Services work order from existing customer

Biovica International
Regulatory press release2026-08-14 08:00

KALLELSE TILL ÅRSSTÄMMA I BIOVICA INTERNATIONAL AB

Biovica International